Durability of Antiretroviral Therapy Regimens and Determinants for Change in HIV-1-Infected Patients in the TREAT Asia HIV Observational Database (TAHOD-LITE)

Abstract

Background

The durability of first-line regimen is important to achieve long-term treatment success for the management of HIV infection. Our analysis describes the duration of sequential ART regimens and identifies the determinants leading to treatment change in HIV-positive patients initiating in Asia.

Methods

All HIV-positive adult patients initiating first-line ART in 2003–2013, from eight clinical sites among seven countries in Asia. Patient follow-up was to May 2014. Kaplan–Meier curves were used to estimate the time to second-line ART and third-line ART regimen. Factors associated with treatment durability were assessed using Cox proportional hazards model.

Results

A total of 16,962 patients initiated first-line ART. Of these, 4,336 patients initiated second-line ART over 38,798 person-years (pys), a crude rate of 11.2 (95% CI 10.8, 11.5) per 100 pys. The probability of being on first-line ART increased from 83.7% (95% CI 82.1, 85.1%) in 2003–2005 to 87.9% (95% CI 87.1, 88.6%) in 2010–2013. Third-line ART was initiated by 1,135 patients over 8,078 pys, a crude rate of 14.0 (95% CI 13.3, 14.9) per 100 pys. The probability of continuing second-line ART significantly increased from 64.9% (95% CI 58.5, 70.6%) in 2003–2005 to 86.2% (95% CI 84.7, 87.6%) in 2010–2013.

Conclusions

Rates of discontinuation of first- and second-line regimens have decreased over the last decade in Asia. Subsequent regimens were of shorter duration compared to the first-line regimen initiated in the same year period. Lower CD4⁺ T-cell count and the use of suboptimal regimens were important factors associated with higher risk of treatment switch.

References

Sterne

J.A.C.

, Hernán

M.A.

, Ledergerber

Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study.

Lancet 2005; 366: 378–384.

Mocroft

, Ledergerber

, Katlama

Decline in the AIDS and death rates in the EuroSIDA study: an observational study.

Lancet 2003; 362: 22–29.

Madec

, Laureillard

, Pinoges

Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia.

AIDS 2007; 21: 351–359.

Spacek

L.A.

, Shihab

H.M.

, Kamya

M.R.

Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.

Clin Infect Dis 2006; 42: 252–259.

May

M.T.

, Sterne

J.A.C.

, Costagliola

HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis.

Lancet 2006; 368: 451–458.

Bendavid

, Holmes

C.B.

, Bhattacharya

, Miller

HIV development assistance and adult mortality in Africa.

JAMA 2012; 307: 2060–2067.

Toure

, Kouadio

, Seyler

Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants.

AIDS 2008; 22: 873–882.

Palella

F.J.

Jr. , Chmiel

J.S.

, Moorman

A.C.

, Holmberg

S.D.

HIV Outpatient Study Investigators. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients.

AIDS 2002; 16: 1617–1626.

Pursuing Later Treatment Option II (PLATO II) project team, Observational HIV Epidemiological Research Europe (COHERE) Group, Costagliola

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study.

Lancet Infect Dis 2012; 12: 119–127.

10.

Parienti

J-J

, Massari

, Descamps

Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.

Clin Infect Dis 2004; 38: 1311–1316.

11.

Bangsberg

D.R.

, Acosta

E.P.

, Gupta

Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness.

AIDS 2006; 20: 223–231.

12.

Chen

R.Y.

, Westfall

A.O.

, Mugavero

M.J.

Duration of highly active antiretroviral therapy regimens.

Clin Infect Dis 2003; 37: 714–722.

13.

Abgrall

, Ingle

S.M.

, May

M.T.

Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.

AIDS 2013; 27: 803–813.

14.

Elzi

, Marzolini

, Furrer

Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.

Arch Intern Med 2010; 170: 57–65.

15.

Wright

, Boyd

M.A.

, Yunihastuti

Rates and factors associated with major modifications to first-line combination antiretroviral therapy: results from the Asia-Pacific region.

PLoS One 2013; 8: e64902.

16.

HIV in Asia and the Pacific. UNAIDS report 2013. 2013. (Accessed 12 June 2017.) Available from http://www.unaids.org/sites/default/files/media_asset/2013_HIV-Asia-Pacific_en_0.pdf.

17.

Srikantiah

, Ghidinelli

, Bachani

Scale-up of national antiretroviral therapy programs: progress and challenges in the Asia Pacific region.

AIDS 2010; 24 Suppl 2: S62–S71.

18.

World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach (2003 revision). Geneva: WHO, 2004. 2003. (Accessed 12 June 2017.) Available from http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf.

19.

Phuphuakrat

, Kiertiburanakul

, Sungkanuparph

Current status of HIV treatment in Asia and the Pacific region.

Sex Health 2014; 11: 119–125.

20.

Zhou

, Li

, Kumarasamy

Deferred modification of antiretroviral regimen following documented treatment failure in Asia: results from the TREAT Asia HIV Observational Database (TAHOD).

HIV Med 2010; 11: 31–39.

21.

De La Mata

N.L.

, Kumarasamy

, Khol

Improved survival in HIV treatment programmes in Asia.

Antivir Ther 2016; 21: 517–527.

22.

World Health Organization. UNAIDS. Treating 3 million by 2005. Making it happen. 2003. (Accessed 12 June 2017.) Available from http://www.who.int/3by5/publications/documents/isbn9241591129/en/.

23.

Antiretroviral Therapy for HIV Infection in Adults and Adolescents: recommendations for a Public Health Approach. 2006: 1–134. (Accessed 15 May 2017.) Available from http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf.

24.

Makinson

, Moing

V.L.

, Kouanfack

, Laurent

, Delaporte

Safety of stavudine in the treatment of HIV infection with a special focus on resource-limited settings.

Expert Opin Drug Saf 2008; 7: 283–293.

25.

Antiretroviral therapy for HIV infection in Adults and Adolescents: recommendations for a public health approach. 2011: 1–156. (Accessed 15 May 2017.) Available from http://apps.who.int/iris/bitstream/10665/44379/1/9789241599764_eng.pdf.

26.

Boettiger

D.C.

, Kerr

, Ditangco

Trends in first-line antiretroviral therapy in Asia: results from the TREAT Asia HIV observational database.

PLoS One 2014; 9: e106525.

27.

Slama

, Li

, Brown

Increases in duration of first highly active antiretroviral therapy over time (1996-2009) and associated factors in the Multicenter AIDS Cohort Study.

J Acquir Immune Defic Syndr 2014; 65: 57–64.

28.

Gonzalez-Serna

, Chan

, Yip

Temporal trends in the discontinuation of first-line antiretroviral therapy.

J Antimicrob Chemother 2014; 69: 2202–2209.

29.

Gallant

J.E.

, Staszewski

, Pozniak

A.L.

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

JAMA 2004; 292: 191–201.

30.

Saag

M.S.

, Cahn

, Raffi

Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial.

JAMA 2004; 292: 180–189.

31.

Madruga

J.R.V.

, Cassetti

, Suleiman

J.M.A.H.

The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy.

HIV Clin Trials 2007; 8: 381–390.

32.

Günthard

H.F.

, Aberg

J.A.

, Eron

J.J.

Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.

JAMA 2014; 312: 410–425.

33.

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2016. (Accessed 20 July 2016.) Available from https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.

34.

Delfraissy

J-F

, Flandre

, Delaugerre

Lopinavir/ ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.

AIDS 2008; 22: 385–393.

35.

T.T.N.

, Ledergerber

, Keiser

Durability and outcome of initial antiretroviral treatments received during 2000–2005 by patients in the Swiss HIV Cohort Study.

J Infect Dis 2008; 197: 1685–1694.

36.

Cicconi

, Cozzi-Lepri

, Castagna

Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naive patients.

HIV Med 2010; 11: 104–113.

37.

Palladino

, Briz

, Bellón

J.M.

Determinants of highly active antiretroviral therapy duration in HIV-1-infected children and adolescents in Madrid, Spain, from 1996 to 2012.

PLoS One 2014; 9: e96307.

38.

Palombi

, Marazzi

M.C.

, Guidotti

Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African Sites with comprehensive monitoring availability.

Clin Infect Dis 2009; 48: 115–122.

39.

ART-LINC of IeDEA Study Group, Keiser

, Tweya

Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring.

AIDS 2009; 23: 1867–1874.

40.

INSIGHT START Study Group, Lundgren JD, Babiker AG, et al.

Initiation of antiretroviral therapy in early asymptomatic HIV infection.

N Engl J Med 2015; 373: 795–807.

41.

TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, et al.

A trial of early antiretrovirals and isoniazid preventive therapy in Africa.

N Engl J Med 2015; 373: 808–822.

42.

Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2014. (Accessed 20 July 2016.) Available from http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf.

43.

Gatell

, Salmon-Ceron

, Lazzarin

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.

Clin Infect Dis 2007; 44: 1484–1492.

44.

Boettiger

D.C.

, Nguyen

V.K.

, Durier

Efficacy of second-line antiretroviral therapy among people living with HIV/AIDS in Asia: results from the TREAT Asia HIV observational database.

J Acquir Immune Defic Syndr 2015; 68: 186–195.